Determinants of serum creatinine trajectory in acute contrast nephropathy

Journal of Interventional Cardiology

Volumn 15, Issue 5, 2002, Pages 349-354

  Guttterez, Noel V ^a   Diaz, Alberto ^a   Timmis, Gerald C ^b   O'Neill, William W ^b   Stevens, Melissa A ^b   Sandberg, Keisha R ^b,c   Mccullough, Peter A ^d  

^a HENRY FORD HOSPITAL   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^d TRUMAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIATRIZOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; GLUCOSE; INFUSION FLUID; MANNITOL; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRYSTALLOID; DIURESIS; FEMALE; HEART CATHETERIZATION; HUMAN; KIDNEY DISEASE; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036775595     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2002.tb01067.x     Document Type: Article

References (14)

1. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-182.
2. Berns JS, Rudnick MR. Radiocontrast media associated nephrotoxicity. Kidney 1992;24:1-6.
3. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
4. Stevens MA, McCullough PA, Tobin K, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. J Am Coll Cardiol 1999;33:403-411.
5. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: Scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
6. Carcoana OV, Hines RL. Is renal dose dopamine protective or therapeutic? Yes. Crit Care Clin 1996;12:677-685.
7. Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation 1997;95:878-884.
8. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: Clinical risk model. Am J Roentgenol 1983;141:1027-1033.
9. Chertow GM, Christiansen CL, Cleary PD, et al. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 1995;155:1505-1511.
10. Zager RA, Foerder C, Bredl C. The influence of mannitol on myoglobinuric acute renal failure: Functional, biochemical, and morphological assessments. J Am Soc Nephrol 1991;2:848-855.
11. Bidani AK, Fleischmann LE, Churchill P, et al. Natriuresis-induced protection in acute myohemoglobinuric renal failure without renal cortical renin content depletion in the rat. Nephron 1978;22:529-537.
12. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction. Kidney Int 1992;41:1408-1415.
13. Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis 1997;30:82-86.
14. Oken DE. Hemodynamic basis for human acute renal failure (vasomotor nephropathy). Am J Med 1984;76:702-710.